Wednesday, February 1, 2017
Reassessing site engagement activities
Reassessing site engagement activities
Perlara, a global patient portal and drug discovery platform company for the one in 10 families affected by rare disease, has announced the formation of a PerlQuest partnership with Michigan-based Maggie’s PMM2-CDG Cure. PMM2-CDG, formerly known as congenital disorder of glycosylation type 1a, is caused by mutations in the evolutionarily conserved gene PMM2. There are currently no FDA approved treatments for PMM2-CDG.
Certara, a provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, has released D360 version 9.0 along with D360 Express, its data informatics platform for discovery scientists. D360 is a self-service data access, integration and visualization solution used to query multiple cheminformatics and bioinformatics data sources and make informed go/no-go and next step research decisions. It is used by more than 5,000 scientists worldwide at both large pharma and specialty research organizations.
University of Oxford and Novo Nordisk has announced a landmark research collaboration focused on type 2 diabetes. The partnership will enable scientists from Novo Nordisk and University of Oxford to collaborate to discover innovative approaches for treating type 2 diabetes. As part of the collaboration, Novo Nordisk is also investing in a new research center on the premises of the University of Oxford.
Neuropore Therapies, a biopharmaceutical company discovering and developing novel therapeutics for the treatment of Parkinson’s disease, Alzheimer’s disease and other neurodegenerative disorders, has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) in support of its Toll-Like Receptor 2 (TLR2) antagonist program focused on modulating neuroinflammation and autophagy in Parkinson’s disease and other neurodegenerative diseases.
For its enormous potential to accelerate the development of personalized cancer therapies, the Gene Editing Institute of Christiana Care Health System’s Helen F. Graham Cancer Center & Research Institute has been awarded a grant of $900,000 from the U.S.-Israel Binational Industrial Research and Development (BIRD) Foundation in partnership with the biotechnology company NovellusDx.
Almac Group, the global contract pharmaceutical development and manufacturing organization, has launched TempEZ—a temperature management software—and the inaugural offering from Almac’s “Next Generation Temperature Management Portfolio.” TempEZ is a web-based platform providing clients with a single database to store temperature data and to ensure regulatory compliance, thereby safeguarding the quality and integrity of drug product.
Lundbeck is collaborating with IBM‘s Watson Health to accelerate the development of innovative medicines to treat psychiatric and neurological disorders. The collaboration will combine Lundbeck’s expertise in the treatment of psychiatric and neurological disorders with IBM’s cognitive and knowledge-based analytics to foster the discovery and development of new innovative treatments of disorders such as schizophrenia and Parkinson’s disease.
Zymeworks, a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer, has opened a state-of-the-art, 10,000 square foot laboratory facility in Vancouver, Canada.
Six of the top 25 largest global pharmaceutical companies announced the formation of Align Biopharma, a new group dedicated to setting technology standards that will make it faster and easier for healthcare professionals (HCPs) to connect with the life sciences industry. Founding members, with input from across the industry, will develop open standards and solutions for companies to streamline how HCPs get the drug and treatment information they need to deliver improved care to patients.